Results of MRC (UK) trial of drug therapy for mild XXXX .

@entity1 @entity1169 @entity64 @entity101 @entity3592 @entity204
The main aim of the trial was to determine whether drug treatment of mild @entity101 (phase V diastolic pressure 90-109 mm Hg) reduced the rates of @entity64 , of @entity204 due to @entity101 , and of coronary events, in @entity1 and @entity1 aged 35-64 years. A total of 17,354 @entity1 was recruited, and 85,572 @entity1 -years of observation accrued. @entity1 were randomly allocated at entry to take @entity3592 or placebo, or @entity1169 or placebo. The @entity64 rate was reduced with treatment (60 @entity64 , vs 109 in the placebo groups), being 1.4 and 2.6 per 1,000 @entity1 -years of observation, respectively (p less than 0.01), but overall rates of coronary events were not different (222 with treatment and 234 with placebos). The incidence of all cardiovascular events was reduced with treatment (286 events, vs 352 with placebos; p less than 0.05). For rates of mortality from all causes, treatment made no difference. Several post hoc analyses of subgroup results were performed. The all-cause mortality was reduced in @entity1 on treatment (157 deaths, vs 181 in placebo groups) but increased in @entity1 on treatment (91 deaths, vs 72 with placebos); this difference between the sexes was significant (p = 0.05). The reduction in @entity64 rate was greater with @entity3592 than with @entity1169 (p = 0.002). The rate of @entity64 was reduced in both smokers and non-smokers taking @entity3592 , but only in non-smokers taking @entity1169 ; this difference between the drugs was significant (p = 0.03). The coronary-event rate was not reduced by @entity3592 , whatever the smoking habit, nor in smokers taking @entity1169 , but it was reduced in non-smokers taking @entity1169 . (ABSTRACT TRUNCATED AT 250 WORDS)
